News and Events

Programs and providers of Obstetrics and Gynecology at Weill Cornell Medicine are often the focus of news stories and features appearing in major national media. We invite you to review some stories that typify the breakthrough accomplishments of our remarkable team and highlight the impact our care has had on patient’s lives.

Weight Loss Drug Linked to Lower Risk of Eye Disease in Patients with Diabetes

close up of man's eye

The popular diabetes and weight loss medication tirzepatide (brand name Mounjaro or Zepbound) may lower the risk of diabetic retinopathy, a leading cause of vision loss, according to Weill Cornell Medicine investigators. The findings may offer comfort to patients concerned about their eye health while taking the drug.

Diabetic retinopathy develops when chronically high blood sugar damages the blood vessels lining the back of the eye and affects nearly 10 million people in the U.S. Previous studies suggested that GLP-1 diabetes and weight loss drugs, such as semaglutide (brand name Wegovy or Ozempic), could worsen diabetic retinopathy and associated conditions. However, the new findings, published Jan. 21 in Ophthalmology, showed that people taking tirzepatide, a similar drug in the same class, were significantly less likely to develop new diabetic retinopathy or progress to more dangerous stages of the disease.  

How Food Shortages Reprogram the Immune System’s Response to Infection

Neutrophils

When food is scarce, stress hormones direct the immune system to operate in “low power” mode to preserve immune function while conserving energy, according to researchers at Weill Cornell Medicine. This reconfiguration is crucial to combating infections amid food insecurity.

“Both famine and infectious disease have been with us throughout our evolutionary history and often occurred at the same time. Yet little is known about how nutrition affects the immune system,” said senior author Dr. Nicholas Collins, an assistant professor of immunology, and a member of the Jill Roberts Institute for Research in Inflammatory Bowel Disease and the Friedman Center for Nutrition at Weill Cornell.

Dr. Nicholas Collins

Dr. Nicholas Collins

Weill Cornell Physician-Scientists Recognized with ASCI Early-Career Awards

lab

Two Weill Cornell Medicine physician-scientists, Dr. Semra Etyemez and Dr. Jesse Platt, have been honored with prestigious early-career awards from the American Society for Clinical Investigation (ASCI) for 2026.

The ASCI is one of the nation’s oldest nonprofit medical honor societies, which is comprised of more than 3,500 physician-scientists from all medical specialties. It recognizes and supports the scientific efforts, educational needs and clinical aspirations of physician-scientists to improve the health of all people. ASCI’s early-career awards are designed to encourage and inspire physician-scientists by engaging them with the ASCI community, while honoring their research achievements.

Dr. Etyemez, a research associate in obstetrics and gynecology and in psychiatry, received the ASCI’s Emerging-Generation Award, which recognizes post-MD, pre-faculty appointment physician-scientists who are meaningfully engaged in immersive research. Her research focuses on the biological mechanisms underlying perinatal mood and anxiety disorders, with the goal of identifying biomarkers and developing strategies to treat and prevent perinatal mental illness.